3CLpro-1 is an
antiviral drug related to
rupintrivir which acts as a
3CLprotease inhibitor and was originally developed for the treatment of human
enterovirus 71. It is one of the most potent of a large series of compounds developed as inhibitors of the viral enzyme
3CL protease, with an in vitroIC50 of 200
nM. It also shows activity against
coronavirus diseases such as
SARS and
MERS, and is under investigation as a potential treatment agent for the viral disease
COVID-19.[1][2][3][4][5][6][7]
3CLpro-1 is an
antiviral drug related to
rupintrivir which acts as a
3CLprotease inhibitor and was originally developed for the treatment of human
enterovirus 71. It is one of the most potent of a large series of compounds developed as inhibitors of the viral enzyme
3CL protease, with an in vitroIC50 of 200
nM. It also shows activity against
coronavirus diseases such as
SARS and
MERS, and is under investigation as a potential treatment agent for the viral disease
COVID-19.[1][2][3][4][5][6][7]